Novo Holdings
Investor profile
Private equityVenture capital
Also recorded as: Novo · Novo Ventures
Deals
53
distinct rounds
Companies
44
backed
Active span
2010–2026
17 yrs
Total round €
€2.4B
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Sofinnova Partners6
- Athos Capital4
- EIFO4
- Export and Investment Fund of Denmark (EIFO)4
- Forbion4
- Andera Partners3
- Gilde Healthcare3
- GIMV3
- INKEF Capital3
- OrbiMed3
- Seventure Partners3
- Wellington Partners3
- Bpifrance2
- EQT Life Sciences2
- Eventide Asset Management2
- Glenview Capital2
- HealthCap2
- Industrifonden2
- Investment Fund of Denmark (EIFO)2
- Invus2
- Ireland Strategic Investment Fund2
- Jeito Capital2
- Kurma Partners2
- Lightstone Ventures2
- Maj Invest Equity2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Quanta | UK | 1 | €205M |
| Freeline Therapeutics | UK | 2 | €178M |
| Circtec | UK | 1 | €150M |
| Fire1 | Ireland | 2 | €139M |
| Amolyt Pharma | France | 1 | €129M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| GlycoEra | Switzerland | 1 | €114M |
| Orbis Medicines | Denmark | 1 | €90M |
| 21st.BIO | Denmark | 1 | €86M |
| ObsEva | Switzerland | 2 | €80M |
| Precirix | Belgium | 1 | €80M |
| Antag Therapeutics | Denmark | 1 | €80M |
| AMSilk | Germany | 2 | €77M |
| Lava Therapeutics | Netherlands | 1 | €70M |
| F2G | UK | 1 | €69M |
| Bactolife | Denmark | 2 | €60M |
| Oxford Nanopore Technologies | UK | 1 | €59M |
| Quanta Dialysis Technologies | UK | 1 | €57M |
| Exscientia | UK | 1 | €55M |
| MinervaX | Denmark | 1 | €54M |
| Numab | Switzerland | 1 | €53M |
| The Protein Brewery | Netherlands | 2 | €52M |
| Subra | Denmark | 1 | €40M |
| MATR Foods | Denmark | 1 | €40M |
| Evosep | Denmark | 1 | €37M |
| NMD Pharma | Denmark | 1 | €35M |
| Coave Therapeutics | France | 1 | €32M |
| Sparrow Quantum | Denmark | 1 | €22M |
| Orphazyme | Denmark | 2 | €18M |
| Corwave | France | 1 | €16M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Quanta | Series D+ | €205M | 2021-06 |
| Circtec | Other | €150M | 2024-05 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Hemab Therapeutics | Series B | €127M | 2023-02 |
| Fire1 | Other | €116M | 2025-01 |
| GlycoEra | Series B | €114M | 2025-05 |
| Freeline Therapeutics | Series C | €107M | 2020-07 |
| Orbis Medicines | Series A | €90M | 2025-01 |
| 21st.BIO | Other | €86M | 2021-12 |
| Antag Therapeutics | Series A | €80M | 2024-12 |